Sabzi Feridoun, Khosravi Donya, Faraji Reza
Preventive Cardiovascular Research Centre Kermanshah, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Department of Gynecology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ethiop J Health Sci. 2015 Oct;25(4):385-9. doi: 10.4314/ejhs.v25i4.15.
One of the rare causes of venous thromboembolism in pregnancy is antithrombin III deficiency. Antithrombin III deficiency is estimated to carry a 30% risk of venous thrombotic complication during each pregnancy and postpartum.
We present thea case of a A 21-year-old pregnant woman (Para 1+) with a history of large atrial septal defect repair at our hospital (Imam Ali Hospital, 2 May 2014). The patient, with unknown history of antithrombin III deficiency, was admitted at our emergency center with dyspnea and chest pain for the rule out of tamponade. She presented with a right atrial thrombosis in the second trimester of pregnancy despite the use of therapeutic doses of heparin and warfarin in the postoperative period as thromboembolic prophylaxis. The risk of warfarin emberyopaty led to termination of pregnancy, and successful redo-cardiac surgery outcome was achieved with the combined use of therapeutic anticoagulation and regular plasma-derived antithrombin concentrate infusions to normalize her antithrombin levels.
She recovered from the operation uneventfully, and wad discharged in the 12(th) postoperative day. In the 6(th) month of follow-up, antithrombin III increased to 70% in more stable level and transethoracic echocardiography showed no recurrence of right atrial thrombus formation. This case leads to further debate regarding whether full anticoagulation should be a worthy preventive measure for venous thromboembolic prophylaxis after an open heart surgery complicated by pregnancy in a women with inherited antithrombin III deficiency. This point may become more relevant as further experience is gained with the use of recombinant human antithrombin in known cases during open cardiac surgery.
抗凝血酶III缺乏是妊娠期静脉血栓栓塞的罕见原因之一。据估计,抗凝血酶III缺乏在每次妊娠和产后发生静脉血栓并发症的风险为30%。
我们报告一例21岁孕妇(孕1产1+),曾于我院(伊玛目阿里医院,2014年5月2日)行大型房间隔缺损修补术。该患者抗凝血酶III缺乏史不详,因呼吸困难和胸痛入住我院急诊中心以排除心包填塞。尽管术后使用治疗剂量的肝素和华法林进行血栓栓塞预防,但她在妊娠中期仍出现右心房血栓形成。华法林胚胎病的风险导致终止妊娠,通过联合使用治疗性抗凝和定期输注血浆源性抗凝血酶浓缩物使她的抗凝血酶水平正常化,成功进行了再次心脏手术。
她术后恢复顺利,术后第12天出院。在随访的第6个月,抗凝血酶III升至70%,处于更稳定水平,经胸超声心动图显示右心房血栓未复发。该病例引发了关于对于患有遗传性抗凝血酶III缺乏的孕妇,在心脏直视手术后,充分抗凝是否应作为预防静脉血栓栓塞的有效预防措施的进一步讨论。随着在心脏直视手术中对已知病例使用重组人抗凝血酶获得更多经验,这一点可能会变得更加重要。